RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$119.89 MLiabilities$297.67 MNon-current liabilities$177.78 MCurrent assets$603.46 MEquity$915.00 MGross equity(calculated)$3.24 BAssets$1.21 BNon-current assets$609.21 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsOther current assetsOther receivablesPrepaid data assetsRestricted cashIntangible assets, netGoodwillProperty and equipment, netOperating lease right-of-use assetsFinancing lease right-of-use assetsOther assets, non-currentRestricted cash, non-currentDeferred tax assetsAccrued expenses and other liabilitiesUnearned revenueOperating lease liabilitiesAccounts payableNotes payable and financing lease liabilitiesUnearned revenue, non-currentOperating lease liabilities, non-currentDeferred tax liabilitiesNotes payable and financing lease liabilities, non-currentOther liabilities, non-currentAdditional paid-in capitalAccumulated other comprehensive incomeCommon stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccrued expenses and other liabilitiesAccrued expenses and other liabilities$56.94 MUnearned revenueUnearned revenue$27.59 MCurrent liabilitiesCurrent liabilities$119.89 MOperating lease liabilitiesOperating lease liabilities$13.25 MAccounts payableAccounts payable$12.67 MLiabilitiesLiabilities$297.67 MNotes payable and financing lease liabilitiesNotes payable and financing lease liabilities$9.44 MUnearned revenue, non-currentUnearned revenue, non-current$112.82 MNon-current liabilitiesNon-current liabilities$177.78 MOperating lease liabilities, non-currentOperating lease liabilities, non-current$39.19 MDeferred tax liabilitiesDeferred tax liabilities$18.31 MCurrent assetsCurrent assets$603.46 MNotes payable and financing lease liabilities, non-currentNotes payable and financinglease liabilities, non-current$4.75 MCash and cash equivalentsCash and cash equivalents$545.68 MEquityEquity$915.00 MOther liabilities, non-currentOther liabilities, non-current$2.70 MGross equity (calculated)Gross equity(calculated)$3.24 BOther current assetsOther current assets$29.32 MAssetsAssets$1.21 BOther receivablesOther receivables$14.39 MPrepaid data assetsPrepaid data assets$8.68 MRestricted cashRestricted cash$5.39 MIntangible assets, netIntangible assets, net$282.89 MNon-current assetsNon-current assets$609.21 MGoodwillGoodwill$160.35 MProperty and equipment, netProperty and equipment, net$89.62 MOperating lease right-of-use assetsOperating lease right-of-use assets$40.27 MAdditional paid-in capitalAdditional paid-in capital$3.21 BFinancing lease right-of-use assetsFinancing lease right-of-use assets$17.18 MOther assets, non-currentOther assets, non-current$12.19 MRestricted cash, non-currentRestricted cash, non-current$5.75 MDeferred tax assetsDeferred tax assets$957.00 KAccumulated other comprehensive incomeAccumulated other comprehensive income$27.99 MCommon stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$5.00 KAccumulated deficitAccumulated deficit−$2.32 B
Chart details

RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,212,668,000 US dollars
Current assets
603,462,000 US dollars
Non-current assets
609,206,000 US dollars
Liabilities
297,665,000 US dollars
Current liabilities
119,886,000 US dollars
Non-current liabilities
177,779,000 US dollars
Equity
915,003,000 US dollars
Cash and cash equivalents
545,683,000 US dollars
Other current assets
29,321,000 US dollars
Other receivables
14,393,000 US dollars
Prepaid data assets
8,680,000 US dollars
Restricted cash
5,385,000 US dollars
Intangible assets, net
282,888,000 US dollars
Goodwill
160,350,000 US dollars
Property and equipment, net
89,623,000 US dollars
Operating lease right-of-use assets
40,271,000 US dollars
Financing lease right-of-use assets
17,179,000 US dollars
Other assets, non-current
12,186,000 US dollars
Restricted cash, non-current
5,752,000 US dollars
Deferred tax assets
957,000 US dollars
Accrued expenses and other liabilities
56,936,000 US dollars
Unearned revenue
27,586,000 US dollars
Operating lease liabilities
13,249,000 US dollars
Accounts payable
12,672,000 US dollars
Notes payable and financing lease liabilities
9,443,000 US dollars
Unearned revenue, non-current
112,818,000 US dollars
Operating lease liabilities, non-current
39,193,000 US dollars
Deferred tax liabilities
18,313,000 US dollars
Notes payable and financing lease liabilities, non-current
4,753,000 US dollars
Other liabilities, non-current
2,702,000 US dollars
Additional paid-in capital
3,211,515,000 US dollars
Accumulated other comprehensive income
27,994,000 US dollars
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
5,000 US dollars
Accumulated deficit
negative 2,324,511,000 US dollars
Gross equity (calculated)
3,239,514,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!